Background Scoping reviews are preliminary assessments intended to characterize the extent and nature of emerging research evidence, identify literature gaps, and offer directions for future research. We conducted a systematic scoping review to describe published scientific literature on strategies to identify and reduce opioid misuse among patients with gastrointestinal (GI) symptoms and disorders. Methods We performed structured keyword searches to identify manuscripts published through June 2016 in the PubMed MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Scopus, and Web of Science databases to extract original research articles that described healthcare practices, tools, or interventions to identify and reduce opioid misuse among GI patients. The Chronic Care Model (CCM) was used to classify the strategies presented. Results Twelve articles met the inclusion criteria. A majority of studies used quasi-experimental or retrospective cohort study designs. Most studies addressed the CCM's clinical information systems element. Seven studies involved identification of opioid misuse through prescription drug monitoring and opioid misuse screening tools. Four studies discussed reductions in opioid use by harnessing drug monitoring data and individual care plans, and implementing self-management and opioid detoxification interventions. One study described drug monitoring and an audit-and-feedback intervention to both identify and reduce opioid misuse. Greatest reductions in opioid misuse were observed when drug monitoring, self-management, or audit-and-feedback interventions were used. Conclusion Prescription drug monitoring and self-management interventions may be promising strategies to identify and reduce opioid misuse in GI care. Rigorous, empirical research is needed to evaluate the longer-term impact of these strategies.
Introduction
The Opioid Epidemic Prescription opioid misuse, overdose, and addiction have reached epidemic proportions in the USA [1, 2] . These trends are characterized by a dramatic rise in opioid use disorders and overdose-related fatalities from medical and non-medical opioid use, as well as higher healthcare utilization and costs [3, 4] . Recent increases in opioid misuse and associated deaths are paralleled by rising opioid prescribing rates to treat acute and chronic pain across a broad range of medical care specialties [5] [6] [7] . In addition, a public perception remains that prescription opioids are safer to abuse than illicit drugs, contributing to deaths due to accidental overdose [8, 9] . Common interactions across prescription drugs and diseases are linked with overdose rates; more than half of overdose-related fatalities involve the concomitant use of psychoactive drugs such as benzodiazepines [10] .
Identifying and implementing evidence-based solutions to address the opioid epidemic is a key national priority [11] . In February 2016, President Obama proposed $1.1 billion in additional funding to reverse the epidemic through expanded access to treatment for opioid abuse. The proposal also delineates a goal to enhance current strategies to reduce inappropriate opioid use through evidence-based prevention programs, prescription drug monitoring and take-back initiatives, and administration of medication-assisted treatment and the overdose reversal drug naloxone [12] . In March 2016, the Centers for Disease Control and Prevention (CDC) issued the updated Guideline for Prescribing Opioids for Chronic Pain, designed to improve communication about the risks and benefits of opioid use for chronic pain, enhance safety and effectiveness of pain treatments, and reduce the risks associated with longerterm opioid therapy [13] .
Building on this broader national effort, a growing body of literature has outlined new steps that regulators, healthcare systems, providers, and patients can take to optimize the use and delivery of opioids [14, 15] . These recommendations promote a shift in focus and call for innovative approaches such as coordinated interventions that meaningfully engage all stakeholders involved. Becker and colleagues have recommended developing validated ways to monitor safety, efficacy, and misuse; creating clear protocols to guide changes in therapy when issues of safety, efficacy or misuse are identified; and using patientcentered treatment plans that emphasize enhanced patientprovider communication around opioid safety [16] . In their recent study, Levy et al. [5] proposed engaging individual medical care specialties with high opioid prescription rates in efforts to develop strategies that effectively reduce inappropriate opioid use. Yet, for many medical care specialties with a high prevalence of opioid prescribing and use, limited data exist around steps taken to reduce inappropriate opioid use.
Opioid Use in Gastrointestinal Care
Evidence suggests that gastrointestinal (GI) care is among an array of medical specialties with rising opioid use [17, 18] . The overall disease burden related to GI disorders has increased substantially over the past decade, affecting an estimated 70 million Americans and contributing to a considerable rise in morbidity, mortality, and healthcare utilization across emergency, inpatient, and outpatient care settings [19] [20] [21] . This has been coupled with patterns of increased opioid prescribing and use to treat a range of painful GI symptoms and disorders [22] [23] [24] . National trends have shown that opioid prescription rates for acute and chronic abdominal pain have doubled in recent decades [24] [25] [26] . The prevalence of opioid use for other GI disorders is also high: recent analyses focused on outpatient opioid use demonstrate that 13-43% of patients with inflammatory bowel disease (IBD), chronic pancreatitis, and functional GI disorders such as irritable bowel syndrome (IBS) use opioids chronically [27] [28] [29] [30] . Moreover, a significant number of patients with GI disorders are considered heavy opioid users and may be prescribed large quantities of opioids per prescription [30, 31] .
Inappropriate opioid use is poorly defined in GI care, yet patterns of increased opioid use among patients with GI disorders are concerning for several reasons. First, limited clinical evidence supports the practice of using of opioid therapy to manage non-malignant chronic abdominal pain, one of the most common GI symptoms [23, 25] . Second, a growing proportion of patients with GI disorders are considered at risk of adverse events associated with opioid misuse and abuse [29, 32, 33] . Factors linked with the greatest risk of opioid misuse in GI care include concurrent pain diagnoses or psychiatric illnesses, frequent healthcare use, and lower quality of life [34] [35] [36] [37] . Third, longer durations of opioid use can paradoxically worsen abdominal pain symptoms and may lead to opioid bowel dysfunction and narcotic bowel syndrome [38] . Finally, for patients with IBD, increased opioid use is associated with decreased quality of life, and increases in 30-day hospital readmissions, serious infections, and complications [39] [40] [41] .
Multiple studies have called for efforts to closely monitor and curb opioid use among patients with painful GI symptoms and disorders [28] [29] [30] . Others have suggested that patients with GI symptoms and disorders who require chronic opioids may represent a unique subgroup that should be better understood in an effort to limit opioid therapy that is not essential [33] . Successful pain management may require going beyond traditional methods and existing pharmacological means to better address pain and improve patient education, quality of life, and healthcare utilization [29, 42] . In their recent editorial, Click et al. [43] suggested that interventions to reduce opioid abuse in this at-risk population are now needed to both improve patient safety and lower healthcare costs. A clear evidence base is lacking, however, that describes approaches used to successfully reduce opioid misuse in GI care. To minimize the risks associated with opioid use across the spectrum of GI care, a critical first step is to document existing strategies that can be used to effectively reduce opioid misuse among patients with GI disorders.
New Contribution
Despite the proliferation of recommendations to address the opioid epidemic, to our knowledge no comprehensive search has been conducted to describe current evidence and strategies that can be used to identify and reduce opioid misuse in the medical care specialty of gastroenterology. Although research has been limited in this area, a small but growing number of studies have focused on the development and adoption of targeted healthcare practices, tools, and interventions that may help to effectively identify and reduce opioid misuse among patients with GI symptoms and disorders. These studies are often limited to a single GI symptom or disorder and are scattered across the broader GI literature that encompasses a wide range of complex conditions. Yet, lessons learned and strategies that focus on identifying and reducing opioid misuse for one GI symptom or disorder may also be relevant and applicable to other GI symptoms and disorders. An in-depth review that brings these strategies together may help to illustrate current strategies that demonstrate particular promise, identify gaps in existing literature, and summarize directions for future research. A scoping review is a valuable tool to assess the breadth and depth of a research topic as a prerequisite to empirical studies and systematic reviews in this area [44] . To this end, the purpose of this systematic scoping review is to evaluate the extent and nature of published scientific literature on strategies, including healthcare practices, tools, and interventions, to identify and reduce opioid misuse among patients with GI symptoms and disorders.
Conceptual Framework
Addressing the opioid epidemic requires the active participation of patients, providers, health systems, regulators, and communities [14, 15] . Evidence-based frameworks such as the Chronic Care Model (CCM) may therefore offer a useful structure to critically appraise strategies to reduce opioid misuse. The CCM centers on active engagement and fostering a sense of collaboration among stakeholders. Cornerstones involve delivering high-quality care that (1) supports patient self-management, (2) is structured around coordinated provider teams, and (3) incorporates clinical information systems to facilitate decision making and productive patient-provider relationships [45, 46] . Defined by Wagner et al. [46, 47] , the CCM illustrates elements considered essential to improve patient outcomes, including self-management, delivery system design, decision support, clinical information systems, health systems, and communities. Implementation of the CCM has been found to improve care processes, reduce costs, and enhance patient outcomes across a myriad of diseases, including diabetes, heart disease, and asthma [48, 49] .
Although originally developed to improve chronic care delivery [46, 47] , the model has been successfully integrated into interventions to address alcohol abuse, opioid misuse, and addiction [50] [51] [52] [53] . Deyo et al. postulated that management of chronic, painful syndromes may also benefit from adoption of the CCM elements, including productive interactions between providers and patients, self-management education, improved care coordination, and harnessing community resources [54] . Adams et al. [55] and Lasser et al. [50] classified a range of healthcare intervention types according to CCM components, demonstrating the model's broader applicability to strengthen interventions [50, 55] . To our knowledge, no published studies have applied the CCM to frame a review of strategies to identify and reduce opioid misuse for patients with GI symptoms and disorders. Given that the CCM elements align closely with current recommendations regarding pain management and opioid use, this is the preferred conceptual framework for this review.
Methods
We conducted this review in accordance with published scoping review guidance Table 1 [44, 56] . We used the PICO method (population, intervention, comparison, and outcome) to create a research question that would guide our literature search [57] . For this review, ''population'' was defined as patients with GI symptoms and disorders; ''interventions'' included healthcare practices, tools, and interventions; no comparison group was used; and ''outcomes'' included (1) identification of and (2) reduction in opioid misuse. We designed the search to answer the following question: What is the extent and nature of published scientific literature on strategies, including healthcare practices, tools, and interventions, to identify and reduce opioid misuse among patients with GI symptoms and disorders?
Data Sources and Searches
A research librarian (L.O.) collaboratively developed the search strategies with the first author (S.B.) and two clinical experts (I.T. and L.K.). In June 2016, searches were conducted in the following databases: PubMed MEDLINE; EMBASE (embase.com); Cochrane Central Register of All databases were searched back to their inception, and no language or date limits were applied. The search terms included prescription drug misuse, inappropriate prescribing; narcotics, opiates, or opioid analgesics; and several painful GI symptoms and disorders for which opioids may be prescribed. A complete list of search strategies and terms used is included in Table 2 .
Abstract Screening
Two reviewers (S.B. and I.T.) independently screened all titles and abstracts and considered articles eligible for inclusion if the abstract described a healthcare practice, tool, or intervention that was applied to identify and/or reduce opioid misuse, abuse, or overuse among patients with any of the following painful GI symptoms and disorders: abdominal pain, biliary dyskinesia, chronic GI-related pain, constipation, functional dyspepsia, functional biliary sphincter disorders, gastroparesis, GI surgical procedures, IBD (including Crohn's disease and ulcerative colitis), IBS, narcotic bowel syndrome, non-cardiac chest pain (GI-related), and pancreatitis. Given that GI symptoms and disorders may also result in pelvic pain, we considered this to be relevant for our review and extended inclusion criteria to studies that potentially included GIrelated pelvic pain. The reviewers determined study eligibility by consensus. We excluded any articles that did not align with these criteria at this stage. Specifically, articles were excluded if they did not address opioid misuse, abuse, or overuse or did not pertain to a GI symptom or disorder. Articles that were not published in English and those that focused on children, animals, and cancer diagnoses were also excluded. Articles went through independent full-text reviews by the two reviewers if the abstracts aligned with the inclusion criteria.
Data Charting and Collation
For each article that was considered eligible for inclusion, both reviewers collected and categorized data as it pertained to the scope of the review. Information gathered from the reviewed articles was entered into data extraction tables and synthesized into a summary format using a data charting form created in Microsoft Excel 2013 (Microsoft Corp, Redmond, WA). We recorded information on authorship, article type, publication year, key study findings, clinical setting, GI patient population, and the type of healthcare practice, tool, and intervention to identify and/or reduce opioid misuse on this form. Using a modified version of the categorization approaches previously published [50, 55] , a second data charting form was adapted to examine and classify the types of healthcare practices, tools, and interventions presented in the articles according to the key CCM components ( Table 3 ). Information that was organized in the data charting forms was used to collate and report the existing approaches toward identifying and reducing opioid misuse, abuse, or overuse in the GI care setting. The reviewers independently extracted data from the included studies using these data charting forms and then collaboratively discussed whether their approach to data extraction was consistent with the overarching research question. Data charting forms were also used to summarize the article findings and facilitate an analytic reinterpretation of the extracted evidence [44] using the CCM.
Results
We retrieved a total of 3236 articles from the search (PubMed MEDLINE: 693; EMBASE: 1049; Cochrane CENTRAL: 28; Scopus: 1241; Web of Science: 225). After removal of duplicates, we screened the titles and abstracts of 2224 unique articles. We excluded 2160 articles as their abstracts did not address the topic of opioid misuse, abuse, or overuse among patients with GI symptoms or disorders. After retrieving and reviewing the full text of the remaining 64 articles, we excluded 52 articles as they did not describe a healthcare practice, tool, or intervention that was applied to identify and/or reduce opioid misuse, abuse, or overuse among patients with GI symptoms and disorders. Twelve articles were ultimately selected for inclusion. We did not identify any additional articles upon manually searching the reference lists of the retrieved articles. A flow diagram of the study search and selection process is included in Fig. 1 .
Summary of Included Articles
The articles selected for inclusion were published between 1999 and 2014, and all studies were conducted in the USA. A majority of studies (n = 8) used a quasi-experimental or retrospective cohort study design, and the remaining studies included case reports and descriptive, cross-sectional studies. The included studies focused on patient populations with the following GI symptoms and/or disorders: abdominal pain (n = 2), chronic pancreatitis (n = 3), GI surgical procedures (n = 1), IBD (n = 4), pelvic pain (n = 1), and narcotic bowel syndrome (n = 1). Most studies (n = 10) were conducted in outpatient care settings, and two were conducted in the emergency setting. Five studies were published in gastroenterology-focused journals, and the remaining studies were published in journals focused on emergency care, managed care pharmacy, pain medicine, psychiatric care, or primary care. The included studies (n = 7) predominantly described a healthcare practice, tool, or intervention solely to identify or screen for opioid misuse, abuse, or overuse among patients with GI symptoms and disorders. Fewer studies (n = 4) discussed a healthcare practice, tool, or intervention to reduce opioid misuse, abuse, or overuse. A single study focused on a healthcare practice, tool, or intervention to both identify and reduce opioid misuse, abuse, or overuse. Table 4 includes the study details of the 12 included articles.
Types of Strategies to Identify and Reduce Opioid Misuse, Abuse, and Overuse
We used the CCM to explore the breadth of existing literature in this area. Specifically, we examined the practices, tools, and intervention components described in the included articles and, using the table derived from Adams et al. [55] and Lasser et al. [50] (Table 3) , mapped each component to a CCM element that best described that component. We found that all strategies discussed in the included articles aligned closely with at least one CCM element, with the majority of articles addressing a strategy to identify or reduce opioid misuse by addressing the clinical information systems element. Table 4 indicates the CCM elements addressed in each study. Discussion of the evidence on these strategies is organized into four subsections below representing the key CCM elements that were addressed: clinical information systems; delivery system design; health systems; and self-management. We found that none of the practices, tools, or interventions fit within the decision support or community categories.
Clinical Information Systems
Of the 12 included articles, eight were categorized into the clinical information systems element of the CCM. These studies largely discussed utilization of prescription drug monitoring programs (PDMPs), clinical registries, and databases to monitor and confirm opioid misuse in a sample of patients with GI symptoms and disorders. Three retrospective cohort studies were focused on characterizing opioid misuse among patients with IBD at a single GI clinic from 2006 to 2011 [58] [59] [60] . The aims of these studies were to use PDMP data to assess the rate of opioid misuse among patients with IBD and to identify potential risk factors associated with misuse. Consistent with other • Search run in June 2016
• Retrieved 1241 articles studies [61] , the authors defined opioid misuse as evidence of opioid prescriptions filled from four or more prescribers and at four or more different pharmacies. The main findings from the PDMP revealed that 17% of the IBD sample were chronic users of opioids, and 66% of chronic users were opioid misusers. The presence of a concurrent functional GI disorder, Crohn's disease, and female gender were among the risk factors associated with opioid misuse in the study sample. The authors recommended evaluation of PDMP data for all patients with IBD who use opioids chronically.
In their case report of a single patient with IBD and chronic abdominal pain, Abraham, Landrey, and Swigris used a statewide PDMP in 2011 to identify chronic opioid abuse and continued opioid prescribing in outpatient and inpatient settings across multiple providers despite a lack of clinician documentation describing pain management goals with opioids [62] . The authors used the case to propose potential solutions to help minimize inappropriate opioid prescribing for chronic abdominal pain, including increasing efforts to document pain intensity, progress toward pain management goals, and the presence of opioidrelated adverse events; educating providers about the features of electronic health records and PDMPs to more easily detect opioid misuse; and, in the case of medical residents, actively engaging attending physicians in the opioid prescribing process.
One prospective, quasi-experimental study described the use of a statewide PDMP to monitor and subsequently reduce opioid prescribing for abdominal pain (among other painful conditions) presenting to a single emergency department (ED) from June through July 2008. In this study, Sinha et al. [63] extracted opioid use data for 174 patients and presented them to attending ED physicians using an audit-and-feedback approach. The ED physicians were also administered a survey to explore factors that influenced opioid prescribing. The authors found high numbers of opioid prescriptions filled in the preceding year (18.9 mean prescriptions per patient). Moreover, individual patients received opioids from an average of 5.6 physicians. After presenting prescribing data to the ED physicians, the authors noted that clinical management of opioids was altered in 41% of cases, with 63% of physicians prescribing fewer or no opioids compared to the original assessment. Physicians commented that reasons for altering their prescribing included knowledge of the number of prescriptions filled, the number of physicians prescribing opioids, and the number of pharmacies filling opioid prescriptions for each patient. Using clinical data and the Internet System for Tracking Over-Prescribing (I-STOP) PDMP, Bahlani et al. [64] conducted a retrospective cohort study over a consecutive 6-month period of 397 patients with chronic pelvic pain and other chronic pain syndromes. The authors sought to describe the use and potential abuse of prescribed medications commonly used to treat pelvic pain. The frequency of opioid and/or benzodiazepine agent use was high across the sample (65.2%). Approximately 3.5% were prescribed duplicate medications by more than one practitioner. Among patients who received duplicate prescriptions, 29% of duplicate medications were benzodiazepines, and 71% were opioids. The authors concluded that implementation of the I-STOP program presented an innovative method to monitor use and identify potential misuse of prescribed controlled substances while allowing patients to obtain medications needed for symptom control.
Outside of the use of PDMP data, Barth et al. [65] and Minkowitz et al. [66] described the use of screening tools administered to identify opioid misuse and opioid-related adverse events. This strategy aligned with clinical information systems as the authors collected and incorporated patient-and population-level data to facilitate efforts to reduce opioid use. In their descriptive, cross-sectional study, Barth et al. [65] used the validated, 17-item Current Opioid Misuse Measure (COMM) survey scale and collected data on quality of life, pain, and depression among a sample of 307 patients with chronic pancreatitis at a single center. The COMM was designed by clinical experts in addiction and pain medicine to understand how patients use their opioid medications. Scoring was based on a 5-point Likert scale; scores of nine or above are generally considered indicative of higher risk of opioid misuse. In this study, the COMM was used to assess opioid misuse and evaluate risk factors associated with misuse among patients with chronic pancreatitis; nearly 40% of patients were at high risk of opioid misuse. Factors associated with higher COMM scores included increased depressive symptoms, alcohol use, and decreased quality of life. Minkowitz et al. [66] reported on the development and validation of a risk score to identify patients at high risk of opioid-related adverse drug events. In this large retrospective cohort analysis, GI surgical patients undergoing colectomy, cholecystectomy, gastrectomy, and gastric bypass procedures (n = 3684) were followed from admission through 30 days post-discharge. Patients were categorized as high or low risk using clinical/demographic characteristics and were evaluated for incidence of opioidrelated adverse events, total hospitalization costs, length of stay, and 30-day readmissions. Risk scores were developed based on International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis codes for GI, respiratory, and genitourinary complications commonly associated with opioid misuse. The authors found a strong association between risk scores and the incidence of opioid-related adverse drug events. Patients at higher risk of experiencing an opioid-related adverse event incurred higher hospitalization costs and longer lengths of stay compared to lower-risk patients. The authors concluded that risk assessment tools can successfully identify high-risk patients and that these data can be used in interventions to reduce opioid-related adverse events [66] .
Delivery System Design
The delivery system design element of the CCM represents steps taken by healthcare providers and systems to deliver coordinated, accessible, and proactive evidence-based care. In this category, Drossman et al. [67] reported on the use of a detoxification program implemented by a multi-disciplinary provider team to reduce opioid use and treat narcotic bowel syndrome. Thirty-nine patients with narcotic bowel syndrome were placed on a 2-year detoxification program; 58% of these patients also had structural GI diagnoses, including IBD and pancreatitis, and/or functional GI diagnoses, including IBS and functional abdominal pain. The program involved gradual discontinuation of opioid medication, and, in parallel, the administration of [67] concluded that despite the promise of detoxification programs, further investigation is needed to understand the high rate of relapse in opioid use.
Health System
In a case series centered on a new standard of care at a single hospital facility, Brice evaluated the use of individualized care plans to enhance opioid pain management and reduce ED utilization among patients with frequent ED visits for painful symptoms including abdominal pain [68] . Individual care plans involved ongoing documentation of interventions and medications received during ED encounters for frequent ED users on a Web-based patient tracking platform. Automatic alerts were sent to all clinical staff when caring for a patient with an individual care plan. Among the 73 patients in the program with individual care plans, 10 patients (14%) returned to the ED for pain management. Although it is unclear whether patients obtained opioid pain medications elsewhere following implementation of the program, the authors concluded that use of individual care plans may help decrease opioid use and drug-seeking behavior in the ED care setting.
Self-Management
Bocelli et al. [69] described implementation of a lifestyle intervention focused on enhancing self-management skills, patient education, and behavioral support to reduce opioid use among patients with chronic pancreatitis. Twenty patients were provided a lifestyle plan emphasizing the timing of pain medications, nutritional supplements, and smoking cessation in an effort to educate patients about pancreatitis. A baseline evaluation and 6-month re-evaluation were conducted to measure demographics, narcotics use, and quality of life measures. The authors found a statistically significant decrease in opioid use following the 6-month period, with a reduction from an average of 96-50 mg oxycodone/day. In addition, they noted a decrease in hospitalizations for chronic pancreatitis and a statistically significant improvement in quality of life. Bocelli et al. [69] concluded that pancreatitis treatment typically focuses on managing pain and nutrition; however, simple lifestyle interventions and patient education may effectively reduce opioid use and improve the lives of patients.
In a case report of a single patient with chronic pancreatitis, Meana et al. [70] reported the use of a behavioral therapy intervention focused on building self-management skills and using non-pharmacological pain management strategies to reduce opioid use. Intervention components included relaxation exercises, behavioral distraction techniques, and self-assessing pain and opioid usage over a 3-month period. The authors measured changes in opioid use, pain scores, mood, and functional status pre-and postintervention and noted a significant improvement in opioid use patterns and decreases in opioid requirements. Study findings indicated a 50% reduction in opioid use, with no increases in pain severity, mood deterioration, or decreases in functional status.
Discussion
Trends of rising opioid misuse, overdose, and addiction necessitate systemic changes to current pain management practices [15, 71] . Increasing opioid use among patients with painful GI symptoms and disorders, in particular, is further complicated by a host of opioid-related adverse effects that can result in new or worsening GI conditions [72] [73] [74] . To derive tailored, evidence-based strategies that minimize inappropriate opioid use in this area, it is essential to understand the unique context surrounding opioid use in GI care and to examine current strategies that have been established. Using Wagner's CCM to frame this review, we learned that few published studies have described strategies to reduce opioid misuse among patients with GI symptoms and disorders; existing strategies fit primarily in the clinical information systems component of the CCM; and several opportunities exist to develop promising new strategies to mitigate the risk of opioid misuse in GI care.
Although opioids are used to treat pain due to a variety of GI illnesses, we found that existing opioid reduction strategies have been used in a relatively small group of GI symptoms and disorders, including abdominal pain, chronic pancreatitis, IBD, and narcotic bowel syndrome. Moreover, a majority of strategies that emerged from this review involved only the identification of potential opioid misuse through PDMPs and, to a lesser extent, opioid misuse risk assessment and screening tools. These studies identified high rates of opioid misuse risk among patients Dig Dis Sci (2017) 62:2668-2685 2681 with chronic pancreatitis and IBD in particular. Five studies discussed reductions in opioid use as a result of specific healthcare practices, tools, or interventions such as harnessing PDMP data [63] and individual care plans [68] , improving patient self-management skills [69, 70] , and adopting an opioid detoxification program [67] . To some extent, these strategies are also reflected in the broader literature focused on chronic pain. Screening tools and PDMPs that track opioid use should be carefully integrated into efforts to enhance the safety and delivery of opioids [75] [76] [77] [78] . In addition, and similar to findings from Drossman et al. [67] , other studies evaluating opioid detoxification programs have yielded modest results and call into question the longer-term effectiveness of detoxification [79, 80] . Interventions that build on patient selfmanagement to reduce opioid use, however, have shown particular promise among patients with chronic pain [81, 82] , and as shown by Bocelli et al. [69] and Meana et al. [70] , may be useful to reduce opioid misuse in chronic pancreatitis and other chronic GI symptoms and disorders. Larger studies are needed to evaluate the impact of self-management interventions on opioid use in the GI care setting.
The CCM was a useful framework to advance our understanding about existing strategies to reduce opioid misuse among patients with GI symptoms and disorders. Most strategies aligned with the clinical information systems element, which calls for incorporating patient and population data to facilitate efficient and effective care [47] . This is understandable given the proliferation of PDMPs and opioid misuse screening tools. The studies we identified, however, generally only extracted data from PDMPs and screening tools and often did not translate this information into opioid use reductions. Leveraging these data into evidence-based interventions will be an important next step to fully realize the potential of clinical information systems. We also identified other key gaps in the literature: some CCM elements, such as decision support and communities, were not addressed at all in the included studies, yet these aspects can be instrumental to reduce opioid misuse. For example, no published, evidence-based guidelines are available to guide GI providers toward safe opioid prescribing to minimize the risk of opioid-related GI adverse effects, although recent reports have indicated a need for evidence-based guidelines to enhance provider decision making around opioid prescribing [16] . The extent to which GI providers adhere to general opioid prescribing guidelines for chronic pain is also unclear. From a community standpoint, prior studies have highlighted the importance of community-based approaches to prevent opioid-related deaths [83] , yet none have been explored in the context of GI care. Kea et al. [84] have suggested that problems with inappropriate opioid use are multifactorial in nature and not linked with a specific care setting, patient characteristic, or provider type. This suggests that interventions grounded in the CCM that actively engage patients, providers, health systems, and communities may be especially beneficial. The CCM has been applied successfully into chronic GI care in the past [85] and may be well suited to structure efforts to reduce opioid misuse in this clinical setting; however, this must be predicated on fully integrating the CCM components into future interventions.
Our findings both characterize past efforts to mitigate opioid misuse in GI care and help to underscore future directions and opportunities to develop new strategies in this area. Many lessons, in particular, can be drawn from current strategies to reduce inappropriate opioid use for chronic pain, given the wider, more robust evidence base. Current recommendations to address rising opioid misuse among patients with chronic pain include using urine drug screening initiatives, adopting patient-provider treatment agreements on adherence to opioid medications, and administering new screening tools such as the Screener and Opioid Assessment for Patients with Pain (SOAPP-Revised) [86] [87] [88] . These strategies did not emerge in our review and, to our knowledge, have not yet been explored in populations with GI symptoms and disorders, but they may offer important benefits. Recent studies within the GI literature have introduced innovative approaches to reduce abdominal pain with opioid alternatives, including tricyclics and other antidepressants, as well as cognitive behavioral therapy [89, 90] . Additionally, Edwards et al. have suggested that inappropriate opioid use in GI care can be reduced by viewing opioids as a temporary therapy only and recognizing concurrent social and psychiatric disorders that may result in higher risk of misuse [33] . Before a full systematic review can be conducted, rigorous empirical studies are needed to test these hypotheses and understand their value to reduce opioid misuse among patients with GI symptoms and disorders.
Several limitations should be acknowledged. Although we attempted to include a wide range of GI symptoms and disorders in our review, it is possible that our search strategy precluded us from capturing opioid mitigation strategies in all GI conditions that require opioid therapy for pain. In addition, given the large variety of search terms related to opioids, opioid misuse, and GI symptoms and disorders, some relevant terms may have been missed. Finally, we did not conduct a quality assessment of the studies included in the review. Although scoping review guidelines typically do not require quality assessments of included studies [44, 56] , we note that because we did not assess the quality of evidence, we are unable to report whether the included studies demonstrate robust or generalizable findings.
Conclusion
In this systematic scoping review, we learned that (1) few published studies have described strategies to reduce opioid misuse among patients with GI symptoms and disorders; (2) existing strategies fit predominantly in the clinical information systems component of the CCM; and (3) several opportunities exist to develop promising new strategies to mitigate the risk of opioid misuse in GI care. Most studies involved only the identification of potential opioid misuse through the application of PDMPs and opioid misuse risk screening tools; these efforts should be expanded to integrate PDMP and screening data into interventions that aim to reduce opioid misuse. Interventions that build patient self-management skills demonstrate some promise in reducing opioid misuse and should be studied in further detail. Given that current knowledge is limited, a need exists for rigorous, empirical research to evaluate the impact of salient strategies emerging from this review as well as those derived from chronic pain literature that may be relevant to GI care. Collectively, these efforts represent an important step forward toward helping address our nation's opioid epidemic.
